<DOC>
	<DOCNO>NCT01094704</DOCNO>
	<brief_summary>Direct measurement mucociliary cough clearance ( MCC/CC ) use biomarker cystic fibrosis ( CF ) . Additional knowledge performance biomarker need inform exploratory clinical trial design support program develop new inhaled therapy CF . We hypothesize MCC/CC measurement use determine durability action agent like hypertonic saline ( HS ) increase epithelial line fluid height .</brief_summary>
	<brief_title>Durability Hypertonic Saline Enhancing Mucociliary Clearance Cystic Fibrosis</brief_title>
	<detailed_description>A reduction epithelial lining fluid height cystic fibrosis ( CF ) consequence decrease function Cystic Fibrosis Transmembrane conductance Regulator ( CFTR ) chloride channel relate increased activity Epithelial sodium ( Na ) Channel ( ENaC ) result impair mucociliary clearance ( MCC ) , mucus stasis , inflammation , infection , ultimately progressive bronchiectasis . Inhalation hypertonic saline ( HS ) , direct osmotic effect airway , result increase epithelial line fluid height vitro increase MCC vivo measure follow inhalation radiotracer gamma scintigraphy ( Sood , et al 2003 ) . MCC biomarker validate clinic , administration inhale hypertonic saline ( HS ) cystic fibrosis patient result short- medium-term improvement MCC ( Donaldson , et al 2006 ) , long-term administration HS associate improvement registration endpoint lung function pulmonary exacerbation ( Elkins , et al 2006 ) . Based large part study , HS gain acceptance CF community , estimate 50 % patient treated therapy . MCC/CC thus excellent choice Proof Concept endpoint exploratory clinical study ENaC modulators . Prior clinical experience ENaC blocker amiloride , improve MCC acutely healthy volunteer ( Sood , et al 2003 ) fail improve lung function long-term study CF ( Pons , et al 2000 ) , suggest durable ENaC modulation require clinical success . It believe modulation ENaC period least 4 hour require achieve necessary durability . This durability also enable twice daily dose . For comparison need know effectiveness HS period . Thus , study intend assess 1 ) duration action 4 hour inhale hypertonic saline ( 7 % ) adult CF patient 2 ) variability MCC/CC measurement without HS treatment . These assessment UNC compare similar measure Johns Hopkins University ( JHU ) Novartis determine feasibility future multicenter study use MCC/CC primary endpoint .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Gender : Male female ( nonpregnant , nonlactating ) Cystic fibrosis document compatible clinical radiographic presentation , sweat chloride &gt; 60 mEq/l 2 disease cause CFTR mutation . Severity Disease : 1 . Must FEV1 great equal 50 % predict screening visit . 2 . Must oxygen saturation &gt; 92 % room air determine pulse oximetry screen visit . Patient legally authorize representative agrees patient/individual 's participation study sign date informed consent form nature study fully explain question satisfactorily answer . Unstable lung disease : As defined change medical regimen precede 2 week ; FEV1 &gt; 15 % recent ( within 6 month ) clinical measurement ; significant new find chest radiograph ( pneumothorax , lobar/segmental collapse ) consider part usual , chronic progression CF lung disease . Patients unable unwilling withdrawn hypertonic saline therapy , dornase alfa , Nacetylcysteine 3 day prior duration Baseline Treatment Period exclude . Patients unable withhold use longacting bronchodilator ( i.e. , Salmeterol , Advair , Formoterol ) , anticholinergic , vest therapy 12 hour prior duration treatment period . Patients unable withhold shortacting bronchodilator 6 hour prior duration treatment period except prescribe study protocol . Patients receive investigational drug therapy precede 30 day . Patients radiation exposure within past year would cause exceed Federal Regulations participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>cystic fibrosis</keyword>
	<keyword>mucociliary clearance</keyword>
	<keyword>hypertonic saline</keyword>
</DOC>